Bladder carcinomas frequently show extensive deletions of chromosomes 9p and/or 9q, potentially including the loci of the Fanconi anemia (FA) genes FANCC and FANCG. FA is a rare recessive disease due to defects in anyone of 13 FANC genes manifesting with genetic instability and increased risk of neoplasia. FA cells are hypersensitive towards DNA crosslinking agents such as mitomycin C and cisplatin that are commonly employed in the chemotherapy of bladder cancers. These observations suggest the possibility of disruption of the FA/BRCA DNA repair pathway in bladder tumors. However, mutations in FANCC or FANCG could not be detected in any of 23 bladder carcinoma cell lines and ten surgical tumor specimens by LOH analysis or by FANCD2 immunoblotting assessing proficiency of the pathway. Only a single cell line, BFTC909, proved defective for FANCD2 monoubiquitination and was highly sensitive towards mitomycin C. This increased sensitivity was restored specifically by transfer of the FANCF gene. Sequencing of FANCF in BFTC909 failed to identify mutations, but methylation of cytosine residues in the FANCF promoter region was demonstrated by methylation-specific PCR, Hpa II restriction and bisulfite DNA sequencing. Methylation-specific PCR uncovered only a single instance of FANCF promoter hypermethylation in surgical specimens of further 41 bladder carcinomas. These low proportions suggest that in contrast to other types of tumors silencing of FANCF is a rare event in bladder cancer and that an intact FA/BRCA pathway might be advantageous for tumor progression.

1.
Agrelo R, Cheng WH, Setien F, Ropero S, Espada J, et al: Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc Natl Acad Sci USA 103:8822–8827 (2006).
2.
Alter BP: Cancer in Fanconi anemia, 1927–2001. Cancer 97:425–440 (2003).
3.
Auerbach AD, Greenbaum J, Pujara K, Batish SD, Bitencourt MA, et al: Spectrum of sequence variation in the FANCG gene: an International Fanconi Anemia Registry (IFAR) study. Hum Mutat 21:158–168 (2003).
4.
Borden LS Jr, Clark PE, Hall MC: Bladder cancer. Curr Opin Oncol 17:275–280 (2005).
5.
Bruch J, Wohr G, Bruderlein S, Barbi G, Wolter H, et al: Detailed marker chromosome analysis in cell line U-BLC1, established from transitional-cell carcinoma of the bladder. Int J Cancer 80:903–910 (1999).
6.
Couch FJ, Johnson MR, Rabe K, Boardman L, McWilliams R, et al: Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res 65:383–386 (2005).
7.
de Bustros A, Nelkin BD, Silverman A, Ehrlich G, Poiesz B, Baylin SB: The short arm of chromosome 11 is a ‘hot spot’ for hypermethylation in human neoplasia. Proc Natl Acad Sci USA 85:5693–5697 (1988).
8.
Dhawan D, Hamdy F, Rehman I, Patterson J, Cross SS, et al: Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J Pathol 209:336–343 (2006).
9.
Dhillon VS, Shahid M, Husain SA: CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in granulosa cell tumors (GCTs) of ovarian origin. Mol Cancer 3:33 (2004).
10.
Elliott AY, Cleveland P, Cervenka J, Castro AE, Stein N, et al: Characterization of a cell line from human transitional cell cancer of the urinary tract. J Natl Cancer Inst 53:1341–1349 (1974).
11.
Elliott AY, Bronson DL, Stein N, Fraley EE: In vitro cultivation of epithelial cells derived from tumors of the human urinary tract. Cancer Res 36:365–369 (1976).
12.
Feinberg AP: Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: an introduction. Cancer Res 59:1743–1746 (1999).
13.
Florl AR, Schulz WA: Peculiar structure and location of 9p21 homozygous deletion breakpoints in human cancer cells. Genes Chromosomes Cancer 37:141–148 (2003).
14.
Florl AR, Steinhoff C, Muller M, Seifert HH, Hader C, Engers R, et al: Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer 91:985–994 (2004).
15.
Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, et al: Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 7:249–262 (2001).
16.
Gibson RA, Buchwald M, Roberts RG, Mathew CG: Characterisation of the exon structure of the Fanconi anaemia group C gene by vectorette PCR. Hum Mol Genet 2:35–38 (1993).
17.
Grossman HB, Wedemeyer G, Ren L, Wilson GN, Cox B: Improved growth of human urothelial carcinoma cell cultures. J Urol 136:953–959 (1986).
18.
Hanenberg H, Batish SD, Pollok KE, Vieten L, Verlander PC, et al: Phenotypic correction of primary Fanconi anemia T cells with retroviral vectors as a diagnostic tool. Exp Hematol 30:410–420 (2002).
19.
Hoffmann MJ, Florl AR, Seifert HH, Schulz WA: Multiple mechanisms downregulate CDKN1C in human bladder cancer. Int J Cancer 114:406–413 (2005).
20.
Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, et al: Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297:606–609 (2002).
21.
Hu N, Li G, Li WJ, Wang C, Goldstein AM, et al: Infrequent mutation in the BRCA2 gene in esophageal squamous cell carcinoma. Clin Cancer Res 8:1121–1126 (2002).
22.
Joenje H, Patel KJ: The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet 2:446–457 (2001).
23.
Joenje H, Arwert F, Eriksson AW, de Koning H, Oostra AB: Oxygen-dependence of chromosomal aberrations in Fanconi’s anaemia. Nature 290:142–143 (1981).
24.
Keen AJ, Knowles MA: Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. Oncogene 9:2083–2088 (1994).
25.
Kennedy RD, D’Andrea AD: The Fanconi anemia/BRCA pathway: new faces in the crowd. Genes Dev 19:2925–2940 (2005).
26.
Kimura F, Florl AR, Seifert HH, Louhelainen J, Maas S, et al: Destabilization of chromosome 9 in transitional cell carcinoma of the urinary bladder. Br J Cancer 85:1887–1893 (2001).
27.
Knowles MA: The genetics of transitional cell carcinoma: progress and potential clinical application. BJU Int 84:412–427 (1999).
28.
Knowles MA: What we could do now: molecular pathology of bladder cancer. Mol Pathol 54:215–221 (2001).
29.
Knowles MA: Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 27:361–373 (2006).
30.
Kyriazis AA, Kyriazis AP, McCombs WB, 3rd, Peterson WD Jr: Morphological, biological, and biochemical characteristics of human bladder transitional cell carcinomas grown in tissue culture and in nude mice. Cancer Res 44:3997–4005 (1984).
31.
Lehmann J, Retz M, Stockle M: Is there standard chemotherapy for metastatic bladder cancer? Quality of life and medical resources utilization based on largest to date randomized trial. Crit Rev Oncol Hematol 47:171–179 (2003).
32.
Levran O, Attwooll C, Henry RT, Milton KL, Neveling K, et al: The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet 37:931–933 (2005).
33.
Lichter P, Cremer T: Chromosome analysis by non-isotopic in situ hybridization, in Rooney DE, Czepulkowski BH (eds): Human Cytogenetics, A Practical Approach, vol I, pp 157–192 (IRL Press, Oxford 1992).
34.
Lin CW, Lin JC, Prout GR: Establishment and characterization of four human bladder tumor cell lines and sublines with different degrees of malignancy. Cancer Res 45:5070–5079 (1985).
35.
Lyakhovich A, Surralles J: Disruption of the Fanconi anemia/BRCA pathway in sporadic cancer. Cancer Lett 232:99–106 (2006).
36.
Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT: Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 23:1000–1004 (2004).
37.
Masters JR: Human cancer cell lines: fact and fantasy. Nat Rev Mol Cell Biol 1:233–236 (2000).
38.
Narayan G, Arias-Pulido H, Nandula SV, Basso K, Sugirtharaj DD, et al: Promoter hypermethylation of FANCF: disruption of Fanconi anemia-BRCA pathway in cervical cancer. Cancer Res 64:2994–2997 (2004).
39.
Neuhausen A, Florl AR, Grimm MO, Schulz WA: DNA methylation alterations in urothelial carcinoma. Cancer Biol Ther 5:993–1001 (2006).
40.
Neveling K, Kalb R, Schindler D: Cancer in Fanconi anemia and Fanconi anemia genes in cancer, in Schindler D, Hoehn H (eds): Monographs in Human Genetics, vol. 15, pp 59–78 (S. Karger, Basel 2007).
41.
Niedernhofer LJ, Lalai AS, Hoeijmakers JH: Fanconi anemia (cross)linked to DNA repair. Cell 123:1191–1198 (2005).
42.
Olopade OI, Wei M: FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell 3:417–420 (2003).
43.
O’Toole C, Nayak S, Price Z, Gilbert WH, Waisman J: A cell line (SCABER) derived from squamous cell carcinoma of the human urinary bladder. Int J Cancer 17:707–714 (1976).
44.
O’Toole C, Price ZH, Ohnuki Y, Unsgaard B: Ultrastructure, karyology and immunology of a cell line originated from a human transitional-cell carcinoma. Br J Cancer 38:64–76 (1978).
45.
Paulie S, Hansson Y, Lundblad ML, Perlmann P: Lectins as probes for identification of tumor-associated antigens on urothelial and colonic carcinoma cell lines. Int J Cancer 31:297–303 (1983).
46.
Rahman N, Seal S, Thompson D, Kelly P, Renwick A, et al: PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39:165–167 (2007).
47.
Rasheed S, Gardner MB, Rongey RW, Nelson-Rees WA, Arnstein P: Human bladder carcinoma: characterization of two new tumor cell lines and search for tumor viruses. J Natl Cancer Inst 58:881–890 (1977).
48.
Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, et al: Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 39:162–164 (2007).
49.
Rigby CC, Franks LM: A human tissue culture cell line from a transitional cell tumour of the urinary bladder: growth, chromosome pattern and ultrastructure. Br J Cancer 24:746–754 (1970).
50.
Sasaki MS, Tonomura A: A high susceptibility of Fanconi’s anemia to chromosome breakage by DNA cross-linking agents. Cancer Res 33:1829–1836 (1973).
51.
Schulz WA: Understanding urothelial carcinoma through cancer pathways. Int J Cancer 119:1513–1518 (2006).
52.
Seal S, Thompson D, Renwick A, Elliott A, Kelly P, et al: Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38:1239–1241 (2006).
53.
Shimamura A, de Oca RM, Svenson JL, Haining N, Moreau LA, et al: A novel diagnostic screen for defects in the Fanconi anemia pathway. Blood 100:4649–4654 (2002).
54.
Swiatkowski S, Seifert HH, Steinhoff C, Prior A, Thievessen I, et al: Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines. Exp Cell Res 282:48–57 (2003).
55.
Taniguchi T, D’Andrea AD: The molecular pathogenesis of Fanconi anemia: recent progress. Blood 107:4223–4233 (2006).
56.
Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, et al: Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 9:568–574 (2003).
57.
Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, et al: CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65:8961–8967 (2005).
58.
Thompson LH, Hinz JM, Yamada NA, Jones NJ: How Fanconi anemia proteins promote the four Rs: replication, recombination, repair, and recovery. Environ Mol Mutagen 45:128–142 (2005).
59.
Tischkowitz M, Ameziane N, Waisfisz Q, De Winter JP, Harris R, et al: Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia. Br J Haematol 123:469–471 (2003).
60.
Tönnies H, Poland J, Sinha P, Lage H: Association of genomic imbalances with drug resistance and thermoresistance in human gastric carcinoma cells. Int J Cancer 103:752–758 (2003).
61.
Tzeng CC, Liu HS, Li C, Jin YT, Chen RM, et al: Characterization of two urothelium cancer cell lines derived from a blackfoot disease endemic area in Taiwan. Anticancer Res 16:179–1804 (1996).
62.
van der Heijden MS, Yeo CJ, Hruban RH, Kern SE: Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 63:2585–2588 (2003).
63.
Wang Z, Li M, Lu S, Zhang Y, Wang H: Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway. Cancer Biol Ther 5:256–260 (2006).
64.
Williams RD: Human urologic cancer cell lines. Invest Urol 17:359–363 (1980).
65.
Williams SV, Sibley KD, Davies AM, Nishiyama H, Hornigold N, et al: Molecular genetic analysis of chromosome 9 candidate tumor-suppressor loci in bladder cancer cell lines. Genes Chromosomes Cancer 34:86–96 (2002).
66.
Williams SV, Adams J, Coulter J, Summersgill BM, Shipley J, Knowles MA: Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro. Genes Chromosomes Cancer 43:315–328 (2005).
67.
Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, et al: Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22:719–729 (2006).
68.
Xia B, Dorsman JC, Ameziane N, de Vries Y, Rooimans MA, et al: Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 39:159–161 (2007).
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.